Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.
作者信息
Zhou Xiaohua Xiao, Ji Hong Jian
机构信息
Department of Nephrology, Yancheng Third People's Hospital, Yancheng, Jiangsu, China
Department of Nephrology, The Sixth Affiliated Hospital of Nantong University, Yancheng, Jiangsu, China.
出版信息
Eur J Hosp Pharm. 2024 Feb 22;31(2):178-179. doi: 10.1136/ejhpharm-2023-003701.
Abstract
摘要
相似文献
1
Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.关于“新型冠状病毒肺炎感染的肾移植受者中奈玛特韦/利托那韦与他克莫司相互作用的管理：三例系列病例”的通信
Eur J Hosp Pharm. 2024 Feb 22;31(2):178-179. doi: 10.1136/ejhpharm-2023-003701.
2
Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.管理 COVID-19 感染的肾移植受者中奈玛特韦/利托那韦和他克莫司的相互作用：三例系列报告。
Eur J Hosp Pharm. 2024 Feb 22;31(2):175-177. doi: 10.1136/ejhpharm-2022-003544.
3
Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.COVID-19 患者接受奈玛特韦/利托那韦联合免疫抑制剂治疗时的免疫抑制剂剂量调整适应策略。
Transpl Int. 2024 Mar 26;37:12360. doi: 10.3389/ti.2024.12360. eCollection 2024.
4
Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.帕克洛维（尼马替韦/利托那韦）与他克莫司在 SARS-CoV-2 感染肾移植患者中的药物相互作用：病例报告。
Transplant Proc. 2022 Jul-Aug;54(6):1557-1560. doi: 10.1016/j.transproceed.2022.04.015. Epub 2022 May 20.
5
The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study.奈玛特韦/利托那韦对肺移植受者他克莫司血药浓度的影响：一项单中心研究。
Pulm Pharmacol Ther. 2024 Mar;84:102280. doi: 10.1016/j.pupt.2023.102280. Epub 2023 Dec 6.
6
A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.一 例 报 告：共 包 装 奈 玛 特 韦 利 托 那 韦 和 他 克 莫 司 致 肺 移 植 受 者 低 钠 血 症 的 药 物 相 互 作 用 。
J Cardiothorac Surg. 2024 Mar 15;19(1):132. doi: 10.1186/s13019-024-02599-w.
7
Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.COVID-19 感染患儿在使用奈玛特韦/利托那韦（Paxlovid）治疗后，他的他克莫司水平升高。
Pediatr Nephrol. 2023 Apr;38(4):1387-1388. doi: 10.1007/s00467-022-05712-0. Epub 2022 Aug 19.
8
Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19.一名23岁感染新冠病毒的女性肾移植患者中帕罗韦德与他克莫司的药物相互作用
Clin Drug Investig. 2022 Aug;42(8):693-695. doi: 10.1007/s40261-022-01180-4. Epub 2022 Jul 11.
9
Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.尼马曲韦/利托那韦治疗 SARS-CoV-2 阳性肾移植受者 - 四例病例系列。
BMC Nephrol. 2023 Apr 15;24(1):99. doi: 10.1186/s12882-023-03154-w.
10
Comment on "Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19".关于“奈玛特韦联合利托那韦与非住院肥胖COVID-19患者结局之间的关联”的评论
Int J Antimicrob Agents. 2024 Feb;63(2):107063. doi: 10.1016/j.ijantimicag.2023.107063. Epub 2023 Dec 14.
本文引用的文献
1
Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.管理 COVID-19 感染的肾移植受者中奈玛特韦/利托那韦和他克莫司的相互作用：三例系列报告。
Eur J Hosp Pharm. 2024 Feb 22;31(2):175-177. doi: 10.1136/ejhpharm-2022-003544.
2
Examination of the Impact of CYP3A4/5 on Drug-Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach.考察 CYP3A4/5 对五味子甲素/五味子乙素与他克莫司（FK-506）药物相互作用的影响：基于生理的药代动力学建模方法。
Int J Mol Sci. 2022 Apr 19;23(9):4485. doi: 10.3390/ijms23094485.
Zotero 插件